Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.

Leukemia - 1 Feb 2022

Cappelli Luca Vincenzo, Meggendorfer Manja, Baer Constance, Nadarajah Niroshan, Hutter Stephan, Jeromin Sabine, Dicker Frank, Kern Wolfgang, Haferlach Torsten, Haferlach Claudia, Höllein Alexander

Abstract excerpt

In AML patients, recurrent mutations were shown to persist in remission, however, only some have a prognostic value and persistent mutations might therefore reflect a re-established premalignant state or truly active disease causing relapse. We aimed to dissect the nature of co-mutations in NPM1 mutated AML where the detection of NPM1 transcripts allows highly specific and sensitive detection of complete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clonal Evolution
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Recurrence, Local

Share to Nucleophosmin

Share to Survival Rate

Share to Transcription Factor CHOP

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 34376804
DOI: 10.1038/s41375-021-01368-1
PMCID: PMC8807394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.PMID 34376804Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.Semantic proximity Read ↗

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapseSemantic proximity Read ↗

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSemantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

The cellular state space of AML unveils novel <i>NPM1</i> subtypes with distinct clinical outcomes and immune evasion propertiesSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.Semantic proximity Read ↗

Overlapping features of therapy-related and de novo NPM1-mutated AML.Semantic proximity Read ↗

Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.Semantic proximity Read ↗

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.Semantic proximity Read ↗

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.